Table 29:
Results of Budget Impact Scenario Analyses
| Year | |||||
|---|---|---|---|---|---|
| 2016 | 2017 | 2018 | 2019 | 2020 | |
| Base Case | |||||
| 3% growth in uptake per year, displacing aspirin (2016 $million) | 1.1 | 3.2 | 5.0 | 6.6 | 7.7 |
| Scenario: Absolute Contraindications | |||||
| 1% growth in uptake per year, displacing aspirin (2016 $million) | 1.1 | 1.8 | 2.5 | 3.3 | 3.8 |
| 5% growth in uptake per year, displacing aspirin (2016 $million) | 1.1 | 4.6 | 8.2 | 11.9 | 15.8 |
| Scenario: Relative Contraindications | |||||
| 3% growth in uptake per year, displacing aspirin (2016 $million) | 1.1 | 46.3 | 89.9 | 128.2 | 157.5 |
| 3% growth in uptake per year, displacing OACs (2016 $million) | 1.1 | 45.3 | 87.8 | 124.7 | 168.8 |
Abbreviation: OAC, oral anticoagulant.